Correction to: Challenges in the Choice of Nonstatin Medications for Low‐Density Lipoprotein‐C Lowering for Cardiovascular Risk Reduction

Figures

• 

  Figure 1. Practical considerations for nonstatin agent selection. †Modest (+); moderate (++); enhanced (+++); ‡Degree of LDL‐C lowering varies with background statin use; §Low cost/easy access = $; Moderate cost/moderate access=$$; High cost/challenging access = $$$; ||Medicare recipients with supplement; #Number of pills/injections per year: Low = #; Moderate = ##; High = ###; **Considered last‐line agents when other nonstatins listed are not indicated,ineffective or not tolerable; *Cardiovascular Outcome Trial data available to support use. FH indicates familial hypercholesterolemia; LDL‐C, low density lipoprotein cholesterol; mAb, monoclonal antibody; PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor; and siRNA, small interfering RNA.